Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis.

Nicosia L, Franzese C, Mazzola R, Franceschini D, Rigo M, D'agostino G, Corradini S, Alongi F, Scorsetti M.

Strahlenther Onkol. 2019 Sep 26. doi: 10.1007/s00066-019-01523-9. [Epub ahead of print]

PMID:
31559480
2.

Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases.

Yeung R, Hamm J, Liu M, Schellenberg D.

Radiat Oncol. 2017 Jun 21;12(1):105. doi: 10.1186/s13014-017-0820-1.

3.

The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer.

Franzese C, Zucali PA, Di Brina L, D'Agostino G, Navarria P, Franceschini D, Santoro A, Scorsetti M.

Cancer Med. 2018 Sep;7(9):4379-4386. doi: 10.1002/cam4.1707. Epub 2018 Aug 2.

4.

Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.

De Bleser E, Jereczek-Fossa BA, Pasquier D, Zilli T, Van As N, Siva S, Fodor A, Dirix P, Gomez-Iturriaga A, Trippa F, Detti B, Ingrosso G, Triggiani L, Bruni A, Alongi F, Reynders D, De Meerleer G, Surgo A, Loukili K, Miralbell R, Silva P, Chander S, Di Muzio NG, Maranzano E, Francolini G, Lancia A, Tree A, Deantoni CL, Ponti E, Marvaso G, Goetghebeur E, Ost P.

Eur Urol. 2019 Jul 19. pii: S0302-2838(19)30533-0. doi: 10.1016/j.eururo.2019.07.009. [Epub ahead of print]

PMID:
31331782
5.

Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes.

Jereczek-Fossa BA, Fanetti G, Fodor C, Ciardo D, Santoro L, Francia CM, Muto M, Surgo A, Zerini D, Marvaso G, Timon G, Romanelli P, Rondi E, Comi S, Cattani F, Golino F, Mazza S, Matei DV, Ferro M, Musi G, Nolè F, de Cobelli O, Ost P, Orecchia R.

Clin Genitourin Cancer. 2017 Aug;15(4):e623-e632. doi: 10.1016/j.clgc.2017.01.004. Epub 2017 Jan 11.

PMID:
28185875
6.

Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences.

Ost P, Jereczek-Fossa BA, Van As N, Zilli T, Tree A, Henderson D, Orecchia R, Casamassima F, Surgo A, Miralbell R, De Meerleer G.

Clin Oncol (R Coll Radiol). 2016 Sep;28(9):e115-20. doi: 10.1016/j.clon.2016.04.040. Epub 2016 Apr 28.

PMID:
27133946
7.

Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".

Rieber J, Streblow J, Uhlmann L, Flentje M, Duma M, Ernst I, Blanck O, Wittig A, Boda-Heggemann J, Krempien R, Lohaus F, Klass ND, Eble MJ, Imhoff D, Kahl H, Petersen C, Gerum S, Henkenberens C, Adebahr S, Hass P, Schrade E, Wendt TG, Hildebrandt G, Andratschke N, Sterzing F, Guckenberger M.

Lung Cancer. 2016 Jul;97:51-8. doi: 10.1016/j.lungcan.2016.04.012. Epub 2016 Apr 26.

PMID:
27237028
8.

Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.

Agolli L, Valeriani M, Nicosia L, Bracci S, De Sanctis V, Minniti G, Enrici RM, Osti MF.

Anticancer Res. 2015 Nov;35(11):6239-45. Erratum in: Anticancer Res. 2016 May;36(5):2629.

PMID:
26504057
9.

Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.

Agolli L, Bracci S, Nicosia L, Valeriani M, De Sanctis V, Osti MF.

Clin Colorectal Cancer. 2017 Mar;16(1):58-64. doi: 10.1016/j.clcc.2016.07.004. Epub 2016 Jul 18.

PMID:
27522627
10.

Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.

Ponti E, Lancia A, Ost P, Trippa F, Triggiani L, Detti B, Ingrosso G.

Eur Urol Focus. 2017 Dec;3(6):538-544. doi: 10.1016/j.euf.2017.07.006. Epub 2017 Aug 8.

PMID:
28801240
11.

Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis.

Franzese C, Di Brina L, D'Agostino G, Franceschini D, Comito T, De Rose F, Tozzi A, Navarria P, Scorsetti M.

J Cancer Res Clin Oncol. 2019 Oct;145(10):2469-2479. doi: 10.1007/s00432-019-03007-w. Epub 2019 Aug 23.

PMID:
31444549
12.

Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.

Battaglia A, De Meerleer G, Tosco L, Moris L, Van den Broeck T, Devos G, Everaerts W, Joniau S.

Eur Urol Oncol. 2019 Mar;2(2):174-188. doi: 10.1016/j.euo.2018.09.005. Epub 2018 Oct 9. Review.

PMID:
31017094
13.

Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer.

Patel PH, Chaw CL, Tree AC, Sharabiani M, van As NJ.

World J Urol. 2019 Jul 25. doi: 10.1007/s00345-019-02873-w. [Epub ahead of print]

PMID:
31346760
14.

Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® Patient Registry.

Mahadevan A, Blanck O, Lanciano R, Peddada A, Sundararaman S, D'Ambrosio D, Sharma S, Perry D, Kolker J, Davis J.

Radiat Oncol. 2018 Feb 13;13(1):26. doi: 10.1186/s13014-018-0969-2.

15.

Salvage Stereotactic Body Radiotherapy for Patients With Prostate Cancer With Isolated Lymph Node Metastasis: A Single-Center Experience.

Ponti E, Ingrosso G, Carosi A, Di Murro L, Lancia A, Pietrasanta F, Santoni R.

Clin Genitourin Cancer. 2015 Aug;13(4):e279-e284. doi: 10.1016/j.clgc.2014.12.014. Epub 2014 Dec 30.

PMID:
25604915
16.

A Large, Multicenter, Retrospective Study on Efficacy and Safety Of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups.

Macchia G, Lazzari R, Colombo N, Laliscia C, Capelli G, D'Agostino GR, Deodato F, Maranzano E, Ippolito E, Ronchi S, Paiar F, Scorsetti M, Cilla S, Ingargiola R, Huscher A, Cerrotta AM, Fodor A, Vicenzi L, Russo D, Borghesi S, Perrucci E, Pignata S, Aristei C, Morganti AG, Scambia G, Valentini V, Jereczek-Fossa BA, Ferrandina G.

Oncologist. 2019 Oct 10. pii: theoncologist.2019-0309. doi: 10.1634/theoncologist.2019-0309. [Epub ahead of print]

PMID:
31601732
17.

Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience.

Ingrosso G, Trippa F, Maranzano E, Carosi A, Ponti E, Arcidiacono F, Draghini L, Di Murro L, Lancia A, Santoni R.

World J Urol. 2017 Jan;35(1):45-49. doi: 10.1007/s00345-016-1860-0. Epub 2016 May 27.

PMID:
27233779
18.

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence.

Decaestecker K, De Meerleer G, Lambert B, Delrue L, Fonteyne V, Claeys T, De Vos F, Huysse W, Hautekiet A, Maes G, Ost P.

Radiat Oncol. 2014 Jun 12;9:135. doi: 10.1186/1748-717X-9-135.

19.
20.

Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT).

Habl G, Straube C, Schiller K, Duma MN, Oechsner M, Kessel KA, Eiber M, Schwaiger M, Kübler H, Gschwend JE, Combs SE.

BMC Cancer. 2017 May 22;17(1):361. doi: 10.1186/s12885-017-3341-2.

Supplemental Content

Support Center